Related Experiment Video
Updated: Jan 21, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
Published on: February 22, 2019
Thymic malignancies: emerging systemic therapies
1Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France.
Purpose Of Review:
The management of thymic malignancies is based on multidisciplinary collaboration. Systemic agents may be administered as an exclusive treatment if local treatment is not achievable. Novel and innovative agents are needed. Integrated genomic analyses reported the activation of targetable signaling pathways in thymomas and thymic carcinomas.
Recent Findings:
Phase II trials reported the antitumor activity of phosphatidylinositol 3-kinase/mechanistic target of rapamycin kinase inhibitors, cyclin dependent kinase inhibitors, and antiangiogenic agents in advanced, refractory thymic malignancies. Meanwhile, a major challenge is the use of immune checkpoint inhibitors, given the frequent association of those tumors with autoimmune disorders.
Summary:
Although those innovative agents were assessed in phase II trials reporting on variable antitumor efficacy in terms of response and survival, in selected and limited cohorts of patients, a better understanding of systemic treatment sequences in a real-life setting is mandatory to analyze the actual efficacy of each line of treatment one after another, define the best clinical-pathological selection of patients for the administration of chemotherapy, targeted agents, and immunotherapy, and develop individualized decision-making to optimize the survival of patients with advanced thymic malignancies.
Insights
Novel systemic agents show promise for advanced thymic malignancies, including phosphatidylinositol 3-kinase/mechanistic target of rapamycin kinase inhibitors and antiangiogenic agents. Further research is needed to optimize treatment sequences and patient selection for improved survival.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Thymic malignancies require multidisciplinary management.
- Systemic therapy is crucial when local treatment is not feasible.
- Genomic analyses reveal targetable pathways in thymomas and thymic carcinomas.
Purpose of the Study:
- To review the role of novel systemic agents in advanced thymic malignancies.
- To discuss challenges and future directions in the treatment of these rare cancers.
Main Methods:
- Review of Phase II clinical trials.
- Analysis of integrated genomic data.
- Assessment of antitumor activity of various systemic agents.
Main Results:
- Phosphatidylinositol 3-kinase/mechanistic target of rapamycin kinase inhibitors, cyclin dependent kinase inhibitors, and antiangiogenic agents demonstrated antitumor activity.
- Immune checkpoint inhibitors present challenges due to autoimmune associations.
- Phase II trials show variable efficacy in selected patient cohorts.
Conclusions:
- Innovative agents are emerging for thymic malignancies.
- Understanding real-world treatment sequences is essential for optimizing efficacy.
- Individualized treatment strategies are needed to improve patient survival.
More Related Videos
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Related Concept Videos
Emerging Adulthood
Introduction Cardiac Emergencies
Gene Therapy
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
Second Order systems I
By reinterpreting the system, one can derive the closed-loop transfer function, which...